<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617405</url>
  </required_header>
  <id_info>
    <org_study_id>PADME1</org_study_id>
    <nct_id>NCT04617405</nct_id>
  </id_info>
  <brief_title>Hormonal and Inflammatory Changes During Pregnancy in Women With Glucose Metabolic Disorders.</brief_title>
  <acronym>HI-MET</acronym>
  <official_title>Hormonal and Inflammatory Changes During Pregnancy in Women With Glucose Metabolic Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first aim of this study is to describe maternal hormonal and inflammatory changes during&#xD;
      pregnancy in women that differ metabolically (limited to women with type 2 diabetes,&#xD;
      gestational diabetes and/or overweight). The second aim of this study is to examine maternal&#xD;
      hormonal, inflammatory and metabolic factors associated with insulin sensitivity in human&#xD;
      pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational study including app. 300 pregnant women from the&#xD;
      outpatient clinics at Department of Obstetrics and Gynecology at Aalborg, Odense and Aarhus&#xD;
      University Hospital.&#xD;
&#xD;
      The study includes 50 healthy normal-weight women, 150 healthy overweight women, 50 women&#xD;
      with gestational diabetes and 50 women with type 2 diabetes.&#xD;
&#xD;
      Hormonal profiles and inflammatory markers will be measured at gestational week 8-10, 10-14,&#xD;
      18-22, 24-28 and 34-38. The blood samples will include HbA1c, glukose, insulin, C-peptid,&#xD;
      lipid profile, liver enzymes, creatinine, FGF-21, TSH, Cortisol, human chorionic&#xD;
      gonadotropin, estradiol, progesterone, prolactin, human placental lactogen, placental growth&#xD;
      hormone, IGF-1, IGF-BP's, Leptin, Adiponectin, GLP-1, GIP, hs-CRP, IL-6, IL-10, IL-1α, IFN-ɣ,&#xD;
      TNF-α, ICAM1, VCAM and CD163. In addition to this, exosomes will be isolated precisely and&#xD;
      profiling of the content of exosomes will be performed using in vitro assays. Proteomics and&#xD;
      miRNAs sequencing will be employed.&#xD;
&#xD;
      Height, weight, and blood pressure will be measured at every visit and a urine sample will be&#xD;
      collected.&#xD;
&#xD;
      Insulin sensitivity will be estimated using the homeostasis model assessment, IS-HOMA, based&#xD;
      on fasting insulin and glucose concentrations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in serum or plasma concentration of metabolic, hormonal and inflammatory markers at four other times during pregnancy.</measure>
    <time_frame>Gestational week 8-10 (baseline), gestational week 10-14, gestational week 18-22, gestational week 24-28 and gestational week 34-38</time_frame>
    <description>Serum concentration of IGF-1, IGFBP-3, IGFBP-1, FGF-21, Leptin, Adiponectin, CD163, Human Chorionic Gonadotropin, Progesterone, C-peptide, Cortisol, Prolactin, Sex Hormone Binding Globulin, Estradiol, Free fatty acids, Human Placental Lactogen and Human Placental Growth Hormone.&#xD;
Plasma concentrations of IL-6, IL-10, IL-1alpha, IFN-gamma, TNF-alpha, ICAM1, VCAM, LDL, HDL, Triglyceride, Gamma-Glutamyl Transferase, Thyrotropin, glucose and HbA1c.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assocation between the serum or plasma concentration of metabolic, hormonal and inflammatory markers Versus Insulin sensitivity at five times during pregnancy.</measure>
    <time_frame>Gestational week 8-10, gestational week 10-14, gestational week 18-22, gestational week 24-28 and gestational week 34-38</time_frame>
    <description>Association between the metabolic, hormonal and inflammatory markers listed as Primary Outcome 1 and the Insulin sensitivity. Insulin sensitivity will be estimated using the homeostasis model assessment (HOMA-IR) based on fasting insulin and glucose concentrations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in the level, content and bioactivity of exosomes in serum and plasma at four other times during pregnancy.</measure>
    <time_frame>Gestational week 8-10 (baseline), gestational week 10-14, gestational week 18-22, gestational week 24-28 and gestational week 34-38</time_frame>
    <description>Exosomes will be isolated and profiling of the content will be performed using SWATH mass spectrometry and miRNA sequencing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association between the level, content and bioactivity of exosomes in serum and plasma Versus Insulin sensitivity at five times during pregnancy.</measure>
    <time_frame>Gestational week 8-10, gestational week 10-14, gestational week 18-22, gestational week 24-28 and gestational week 34-38</time_frame>
    <description>Exosomes will be isolated and profiling of the content will be performed using SWATH mass spectrometry and miRNA sequencing. Insulin sensitivity will be estimated using the homeostasis model assessment (HOMA-IR) based on fasting insulin and glucose concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood pressure (systolic and diastolic) at four other times during pregnancy.</measure>
    <time_frame>Gestational week 8-10 (baseline), gestational week 10-14, gestational week 18-22, gestational week 24-28 and gestational week 34-38</time_frame>
    <description>Blood pressure includes the measurement of both systolic and diastolic blood pressure (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in body weight at four other times during pregnancy.</measure>
    <time_frame>Gestational week 8-10 (baseline), gestational week 10-14, gestational week 18-22, gestational week 24-28 and gestational week 34-38</time_frame>
    <description>Body weight measured in kilograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between the blood pressure (systolic and diastolic) Versus Insulin sensitivity at five times during pregnancy.</measure>
    <time_frame>Gestational week 8-10, gestational week 10-14, gestational week 18-22, gestational week 24-28 and gestational week 34-38</time_frame>
    <description>Blood pressure includes the measurement of both systolic and diastolic blood pressure (mmHg). Insulin sensitivity will be estimated using the homeostasis model assessment (HOMA-IR) based on fasting insulin and glucose concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between the body weight Versus Insulin sensitivity at five times during pregnancy.</measure>
    <time_frame>Gestational week 8-10, gestational week 10-14, gestational week 18-22, gestational week 24-28 and gestational week 34-38</time_frame>
    <description>Body weight measured in kilograms. Insulin sensitivity will be estimated using the homeostasis model assessment (HOMA-IR) based on fasting insulin and glucose concentrations.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Gestational Diabetes</condition>
  <condition>Overweight and Obesity</condition>
  <condition>Pregnancy in Diabetic</condition>
  <condition>Insulin Resistance</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Pregnancy, High Risk</condition>
  <arm_group>
    <arm_group_label>Type A</arm_group_label>
    <description>Healthy normal-weight pregnant women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type B</arm_group_label>
    <description>Pregnant women with gestational diabetes diagnosed at early screening (before gestational week 20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type C</arm_group_label>
    <description>Pregnant women with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type D</arm_group_label>
    <description>Healthy overweight pregnant women</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions</intervention_name>
    <description>No interventions</description>
    <arm_group_label>Type A</arm_group_label>
    <arm_group_label>Type B</arm_group_label>
    <arm_group_label>Type C</arm_group_label>
    <arm_group_label>Type D</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consist of pregnant women followed at The Department of Gynaecology&#xD;
        and Obstetrics at Aarhus University Hospital, Aalborg University Hospital or Odense&#xD;
        University Hospital. Cases are either healthy with a BMI &gt;= 25, diagnosed with gestational&#xD;
        diabetes before gestational week 20 or diagnosed with pregestational type 2 diabetes.&#xD;
        Controls are healthy with a BMI &lt; 25.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women at The Department of Gynaecology and Obstetrics at Aarhus University&#xD;
             Hospital, Aalborg University Hospital or Odense University Hospital.&#xD;
&#xD;
          -  Women have to be in 1 of 4 categories: Healthy with a BMI &lt; 25, healthy with a BMI &gt;=&#xD;
             25, diagnosed with gestational diabetes before gestational week 20 or diagnosed with&#xD;
             pregestational type 2 diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Not able to read and understand danish&#xD;
&#xD;
          -  Previous bariatric surgery&#xD;
&#xD;
          -  Treatment with systemic corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only pregnant women are eligible for participation.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anna S Koefoed, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna S Koefoed, M.D.</last_name>
    <phone>+45 93 50 80 69</phone>
    <email>annask@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per G Ovesen, Prof., M.D.</last_name>
    <email>perovese@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna S Koefoed, M.D.</last_name>
      <phone>+45 93 50 80 69</phone>
      <email>annask@clin.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Per G Ovesen, Prof., M.D.</last_name>
      <email>perovese@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne W Sørensen, M.D.</last_name>
      <phone>+45 93 50 80 69</phone>
      <email>anns@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Lotte T Andersen, MD</last_name>
      <phone>+45 93 50 80 69</phone>
      <email>lise.lotte.andersen@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

